Kimberley Evason

Has grant

Associate Professor

University of Utah
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Hepatic stellate cells in liver development and cancer

Open Date: 2022-07-01

Close Date: 2026-06-30

Articles (12)

miR-146a −/− Ccl5 −/− DKO female mice have lower tumor burden and MDSC-like cell infiltration, but greater weight gain than miR-146a −/− female mice in DEN-CDHFD–instigated HCC. A, qRT-PCR for Ccl5 expression in immune cells isolated via FACS with anti-CD45 antibody from WT or miR-146a −/− mice and from miR-146a −/− Ccl5 −/− DKO mice to verify detection of Ccl5 . B–D, Suppression of miR-146a −/− macroscopic and microscopic tumor formation phenotype by deletion of Ccl5 and overall liver morphology. E and F, miR-146a −/− CD8 + T-cell phenotypes after additional deletion of Ccl5 and representative flow plots. G, Suppression of exacerbated MDSC-like cells from the loss of miR-146a by additional deletion of Ccl5 and representative flow plot. H, Cumulative weight gain increases due to miR-146a −/− in the DEN-CDHFD time course are not suppressed but are exacerbated by additional Ccl5 mutation. I and J, Increased general non-HCC liver pathology in miR-146a −/− does not require CCL5, as indicated by a lack of suppression of liver weight and steatohepatitis in DKO animals. Steatohepatitis inflammation scoring was conducted as described in Fig. 3F . Bar charts contain dots representing individual mice and error bars representing mean ± SEM. The percentage of weight gain line graph ( H ) displays points and error bars that are the mean ± SEM of 6 WT, 10 miR-146a −/− , and 7 DKO mice. *, P P P P

Year:

2026

Ccl5 is highly associated with aging miR-146a −/− CD8 + T cells, and its expression is elevated in miR-146a −/− male and female mice. A, scRNA-seq analysis of samples from young and aged (15 months) WT or miR-146a −/− splenocytes from male and female mice using CIPR to annotate cell populations and to localize Ccl5 expression in UMAP plot clusters. B and C, Increased Ccl5 expression in aged miR-146a −/− CD8 + effector T cells from the same mice as A . D, Flow analysis in CD8 + T cells shows increased CCL5 staining in female miR-146a −/− liver. E, qRT-PCR for Ccl5 expression in sorted CD8 + T cells from female WT or miR-146a −/− splenocytes. F–H, qRT-PCR analysis of Ccl5 , Gzmk , and Pdcdc1 (PD-1), respectively, in livers from WT or miR-146a −/− DEN-CDHFD–treated female mice. I, Quantification and representative flow plots of age-associated CD8 T cells (Taa cells) in the liver of male and female WT and miR-146a −/− aged, cancer-free mice. J, Surface marker expression profile of Taa cells in male and female WT and miR-146a −/− aged, cancer-free mice relative to an unstained liver sample. Bar charts contain dots representing individual mice, and error bars represent mean ± SEM. *, P P P P

Year:

2026

Steatohepatitis in nontumor regions of DEN-treated WT and miR-146a −/− female mouse livers. A, WT mouse liver, showing no significant steatosis, hypertrophy, or inflammation. B, miR-146a −/− liver, showing macrovesicular steatosis (arrows) and zones of microvesicular steatosis and hypertrophy (lower right of dashed line). C, WT mouse liver, showing a central vein with surrounding unremarkable hepatocytes. D, miR-146a −/− genotype, showing two clusters of inflammatory cells (circled) and hypertrophy. Some hypertrophied hepatocytes contain microvesicular steatosis (arrowheads), whereas others have rarified cytoplasm and Mallory–Denk bodies similar to ballooned hepatocytes in human patients (arrow). H&E stains. Scale bars are 40 μm. A and B, Magnification 20×. C and D, Magnification 40×. E, Non-alcoholic fatty liver disease activity scores (NAS). Scores were calculated on a nine-point scale with the nine points being derived from a sum of these measurements: hepatocyte hypertrophy, inflammation, and steatosis using an established scoring system ( 52 ). F, Inflammation score (Fisher’s exact test, separated between 0–2 and 3). G, Fat cores: 0 ≤ 5% fat; 1 = 5%–33% fat; 2 = 33%–66% fat; 3 ≥ 66% fat. H, Hypertrophy score (Fisher’s exact test, separated between 0–2 and 3). The data represent three experiments. Bar chart ( E ) displays points representing individual mice and error bars representing mean ± SEM. *, P P

Year:

2026

miR-146a protects females from DEN-induced HCC but is not fully sufficient to protect males. A, Loss of miR-146a reduces cumulative weight gain over 35 weeks on CDHFD in DEN-treated females. B, Increased AFP and ALT markers of liver injury and HCC during the 35-week course on CDHFD in DEN-treated miR-146a −/− females. C, Increased incidence of visible liver tumors and liver mass in miR-146a −/− females after 35 weeks on CDHFD with DEN treatment, quantified in D . E, Increased IL6 expression by qRT-PCR in livers from female mice in the absence of miR-146a . F, Percentage of weight gain over 35 weeks on CDHFD in DEN-treated WT or miR-146a −/− males. G, AFP and ALT markers of liver injury and HCC during the 35-week course on CDHFD in DEN-treated WT or miR-146a −/− males. H, Incidence of visible liver tumors and liver mass in WT or miR-146a −/− males after 35 weeks on CDHFD with DEN treatment, quantified in I . J, Liver IL6 expression in WT or miR-146a −/− males. Data represent three experiments; percentage of weight gain line graphs display mean ± SEM ( A and F ) for 22 miR-146a −/− mice and 13 WT mice or 12 miR-146a −/− and 19 WT mice, respectively. AFP and ALT line graphs display points representing each mouse, with means connected by lines ( B and G ). Bar charts display points representing each mouse and error bars that are mean ± SEM. In all charts, *, P P P P

Year:

2026

The miRNA microRNA-146a ( miR-146a ) regulates several aspects of chronic inflammation, including the hepatocellular carcinoma (HCC) risk factor, steatohepatitis. In this study, we find that the loss of miR-146a leads to a significantly increased tumor burden over a 9-month time frame in a mouse model of HCC. Notably, this miR-146a −/− phenotype is most pronounced in females, who are typically not sensitive to this model. Mechanistically, we identified increases in dysfunctional CD8 + T cells that express high levels of CCL5 and resemble age-associated T (Taa) cells, as well as elevated levels of myeloid cells with a myeloid-derived suppressor cell (MDSC) phenotype, a class of myeloid cells that suppresses tumor immunity. Deletion of Ccl5 from miR-146a –deficient mice returned tumor growth and the aberrant myeloid cell populations to wild-type levels. Surprisingly, deletion of Ccl5 did not rescue the gross metabolic phenotype observed in miR-146a −/− mice subjected to HCC induction, indicating that miR-146a plays an independent role in regulating HCC and metabolic disease. Taken together, this work reveals a critical host-protective role for miR-146a in HCC that is mechanistically dependent on CCL5 and wherein tumor burden correlates with two suppressive immune populations, providing an impetus for targeting these pathways to combat HCC. Furthermore, the correlations with tumor burden and Taa cells suggest that aging may increase HCC risk through the accumulation of CCL5-expressing Taa cells. Significance: The findings in this study highlight the potential of a miRNA-based therapy in the treatment of, and as a biomarker for, liver cancer, something especially promising given the liver’s avid uptake of RNA. Additionally, this work reveals possible causal roles in liver cancer for two unique immune cell types that are prevented by miR-146a.

Year:

2026

Tumor-bearing female miR-146a −/− mouse livers contain increased PD-1 + CD8 T cells and increased aberrant myeloid populations. A, Significantly increased CD8 + T cells were seen in miR-146a −/− livers although no significant change ( B ) in CD4 + T cells from miR-146a −/− livers was observed. C, Representative flow plots for ( A ) and ( B ), showing CD4 + and CD8 + populations in CD45 + lymphocytes. D and E, Frequency and representative flow plots for PD-1 + CD8 T cells from WT and miR-146a −/− liver lymphocytes. F and G, Frequency and representative flow plots for cells with the surface marker profile of MDSCs (MDSC-like) in the CD11b + population from WT and miR-146a −/− liver. H and I, Frequency of and representative flow plots of two populations of myeloid cells (M-MDSC–like cells and maturing monocytes). Bar charts contain dots representing individual mice, and error bars represent mean ± SEM. *, P P P P

Year:

2026

DEN-CDHFD–treated miR-146a female mice have an increased proportion of CCL5-expressing dysfunctional CD8 T cells and an aberrant monocyte population according to scRNA-seq. A, UMAP displaying annotated cell clusters revealed by scRNA-seq using mouse livers. B, The levels of a T cell and monocyte cluster in 2-month-old WT mice, DEN-CDHFD–treated WT mice, DEN-CDHFD–treated miR-146a −/− mice, and DEN-CDHFD–treated miR-146a −/− ; Ccl5 −/− mice (left to right). DEN-CDHFD–treated mice are 35 weeks old at the endpoint. C, T-cell 1 cluster is composed of CD8 + T cells expressing markers associated with Taa cells, including Ccl5 . D, Myeloid markers identifying the monocyte 4 cluster, including Itgam , for which the monocyte 4 cluster has higher expression than other monocyte clusters. scRNA-seq data have been uploaded to the NCBI Gene Expression Omnibus database (GSE300674).

Year:

2026

Examples of lesions in DEN-treated WT and miR-146a −/− female mouse livers. A and B, Focus of cytologic alteration (FCA). At 10× ( A ), the lesion appears as a small (less than 2 mm) zone of more darkly staining hepatocytes. At 40×, nonlesional hepatocytes at the periphery of the lesion (top) appear larger than cells within the FCA (bottom). C and D, Hepatocellular adenoma (HCA). At 4× ( C ), the tumor can be seen to distort the liver capsule (arrow), and no normal portal tracts are seen within the lesion. At 20× ( D ), nonlesional hepatocytes at the periphery of the lesion (top left) are compressed. E and F, HCC. At 4× ( E ), the tumor shows a zone of necrosis (arrow). The lesion lacks normal portal tracts, and the surrounding nonlesional hepatocytes are compressed. Nuclear enlargement, nuclear contour irregularities, increased nuclear-to-cytoplasmic ratios, and architectural disarray are seen at 40× ( F ). H&E stains. Scale bars are 40 μm ( A , B , D , and F ) or 400 μm ( C and E ). G, Microscopic tumors were counted from one right lobe of each liver. H, Tumor severity and size. 0 = no tumor; 1 = FCA ≤1 mm; 2 = FCA >1 mm; 3 = HCC or HCA ≤2 mm; 4 = HCC or HCA >2 mm (*Fisher’s exact test separated between HCA/HCC and non-HCA/HCC). Data represent three experiments. The bar chart ( G ) displays points representing individual mice and error bars representing mean ± SEM. *, P P

Year:

2026

Metabolic-associated steatohepatitis (MASH) involves hepatocyte damage that cannot be explained solely by lipid accumulation. Here, to discover injury-specific pathways, we focused on a gene of uncertain function, EF-Hand Domain Family Member D1 (EFHD1), identified in human genome-wide association studies of liver injury but not liver fat. We show that EFHD1, a Ca 2+ -dependent actin crosslinker, stabilizes endoplasmic reticulum–mitochondria contact sites (ERMCS), detecting spatiotemporal coincidence of inter-organellar proximity and ER Ca 2+ release. During MASH, EFHD1 upregulation drives pathological mitochondrial fragmentation via excessive contact persistence. This structural failure promotes mitochondrial double-stranded RNA escape and activation of a maladaptive antiviral PKR-dependent stress response, a causal relationship also supported by Mendelian randomization in humans. Consequently, inhibiting EFHD1 in human and mouse models blunts hepatocyte damage. These findings identify EFHD1 as a Ca 2+ -dependent ERMCS stabilizer, reveal a hepatocyte-intrinsic injury pathway, and suggest EFHD1 inhibition as a therapeutic strategy.

Year:

2026

Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that plays a role in the regulation of redox homeostasis and cellular metabolism. Activating mutations in the NRF2 pathway have been identified in approximately 15% of liver cancer patients. However, the mechanisms by which NRF2 promotes liver tumorigenesis are poorly understood. Employing a transgenic zebrafish model with hepatocyte-specific, inducible expression of a clinically relevant constitutively active NRF2 mutant (NRF2 T80K ), we show that constitutive activation of NRF2 drives hepatocyte to cholangiocyte transdifferentiation. Importantly, we demonstrate that NRF2 affects liver cell plasticity in a cell-autonomous, evolutionarily conserved, and reversible manner. Utilizing an epigenetic-focused chemical screen, the BRG1/BRM inhibitor FHD-286 was identified as a potent suppressor of NRF2-driven transdifferentiation. Overall, our study reveals a novel role for NRF2 in the regulation of liver cell plasticity during tumour initiation and identifies a therapeutic approach to overcome the oncogenic activity of NRF2.

Year:

2026

Year:

2026

Year:

2025

Collaborators (16)

Ryan O'Connell

Professor

University of Utah

UNITED STATES
View details

Yingzi Yang

Professor

Harvard University

UNITED STATES
View details

Amandine Chaix

University of Utah

UNITED STATES
View details

Sihem Boudina

University of Utah

UNITED STATES
View details

Vivek Garg

Assistant Professor

University of Maryland

UNITED STATES
View details

Andrew Cox

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Molly Gallop

Assistant Professor

Earlham College

UNITED STATES
View details

Enrique Balderas-Angeles

University of Utah

UNITED STATES
View details

Jared Rutter

Professor

University of Utah

UNITED STATES
View details

Dipayan Chaudhuri

University of Utah

UNITED STATES
View details

Scott Summers

Co-Director

University of Utah

UNITED STATES
View details

Micah J. Drummond

University of Utah

UNITED STATES
View details

William L. Holland

Associate Professor

University of Utah

UNITED STATES
View details

Patrice N Mimche

Associate Professor

Indiana University School of Medicine

UNITED STATES
View details

Kristin Brown

Senior Research Fellow

University of Melbourne

AUSTRALIA
View details

Robin Shaw

Director

University of Utah

UNITED STATES
View details